There are moments in clinical research that don’t show up in timelines, protocols, or dashboards. They happen in exam rooms, in long conversations with doctors, and in the quiet realization that there is no approved treatment for what you’ve just been diagnosed with. 

For Joe Tyler, one of Welo Life Science’s Business Development Directors, that moment came in his early 30s. After years of misdiagnosis, he finally received a diagnosis of Friedreich’s ataxia (FA), a rare, degenerative neuromuscular disease with no approved therapy. 

Living With Uncertainty 

FA is progressive, affecting coordination, balance, and muscle control. For many patients, symptoms begin early in life. For Joe, they appeared later, which made the path to diagnosis longer and more difficult, marked by multiple specialists, years of uncertainty, and eventually confirmation through genetic testing. 

But diagnosis is only one part of the journey. What comes next is often harder: understanding what you’re facing, without knowing whether anything can be done about it. 

Why Patients Choose Clinical Trials 

For Joe, the decision came down to one question, if there isn’t a treatment yet, how does one get developed? His answer was participation. Clinical trials offered a way to contribute, even without a guaranteed outcome, and that motivation is far from uncommon. Many rare disease patients choose to participate not only for themselves, but for the people who may come after them. 

Clinical teams understand this well. Participation isn’t simply a matter of eligibility; it’s about access, trust, and the ability to engage patients in a way that feels meaningful rather than transactional. 

When Progress Isn’t Linear 

Joe enrolled in multiple studies over time. Some focused on measurement, others on safety. Eventually, he joined a trial for a therapy that showed real promise. Patients began noticing changes. Symptoms stabilized. Cautious optimism started to build within the community. 

And then the therapy wasn’t approved, not once, but multiple times. The reason was familiar to anyone working in clinical development: there wasn’t enough data. For rare diseases, this challenge is constant. Patient populations are small, and even when outcomes are genuinely meaningful, demonstrating statistical certainty can be extraordinarily difficult. 

From a regulatory perspective, the decision made sense. From a patient perspective, it was hard to reconcile. You can feel something working. You can see the impact across others in the trial. And still, it isn’t enough. 

When Patients Drive Momentum 

What happened next didn’t come from a system or a sponsor; it came from the patient community itself. Advocacy groups, families, researchers, and patients came together to push for progress, and a letter to the FDA gathered more than 70,000 signatures. For a rare disease community, that level of coordination is remarkable, and it reflects something important about clinical research more broadly: patients are not passive participants. They are active stakeholders in the outcome. 

In early 2023, the therapy was approved. For the first time, patients with FA had an option to slow the progression of their disease. 

The Role of Access in Clinical Trials 

Approval, though, is only part of the story. For rare diseases, patients are geographically dispersed, and the clinical trials that generate the data needed for approval depend on the ability to reach people across countries, regions, languages, and healthcare systems. When access is limited, participation is limited, and when participation is limited, progress slows. 

That means access isn’t just a logistical concern. It’s a scientific one. Patients need information they can actually understand, trials they can realistically take part in, and communication that builds genuine trust over time. 

“As a rare disease patient, my favorite solution we provide to our clients is linguistic validation, especially cognitive debriefing. We can help our clients ensure the translated version of PRO’s, COA’s, etc. are not only accurate linguistically but also appropriate culturally and conceptually equivalent for the target population. We can ensure everyone globally interprets content the same way and, if the therapy works as intended, can help speed approvals.” – Joe Tyler – Welo Life Sciences, BDD

Seeing Clinical Trials From Both Sides 

Joe’s perspective is unusual. He has participated in clinical trials as a patient, and he also works in life sciences, supporting organizations that run them. He understands both the operational complexity of global studies and the lived experience of waiting for outcomes, and that dual vantage point reinforces a truth that’s easy to lose sight of in the day-to-day work of clinical development: trials are designed around data, but they move forward because of people. 

A Different Way to Think About Progress 

Clinical research is typically measured in milestones, study start, enrollment targets, regulatory submissions. But for patients, progress is experienced differently. It’s measured in time, in uncertainty, and in the hope that participation, however small it may feel in the moment, is contributing to something larger than any single trial. 

Behind every protocol and every submission, there are patients making a decision to take part without knowing the outcome. In many cases, that decision is exactly what makes progress possible. 

Global clinical trials depend on the ability to reach and support diverse patient populations. Welo Life Sciences helps organizations design multilingual workflows that improve access, support participation, and enable more representative studies.